Amgen’s Rocatinlimab Study: A Boost for Vaccine Response in Atopic Dermatitis

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.

Amgen Inc. recently completed a Phase 3 clinical study titled ‘A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET – VOYAGER).’ The study aimed to evaluate the effect of Rocatinlimab on vaccine antibody responses in adults with moderate-to-severe atopic dermatitis. The primary objectives were to estimate the vaccine response in the Rocatinlimab group compared to the placebo group, focusing on anti-tetanus and anti-meningococcal antibodies at Week 24.

The intervention tested was Rocatinlimab, a drug administered via subcutaneous injection every four weeks, with a loading dose at Week 2. The study also included a placebo group for comparison.

This interventional study was randomized with a parallel assignment model and double masking, involving both participants and investigators. The primary purpose was basic science, aiming to understand the biological effects of Rocatinlimab on vaccine responses.

The study began on June 7, 2023, and was completed with the last update submitted on July 1, 2025. These dates are crucial as they mark the timeline of the study’s progression and data availability.

The completion of this study could influence Amgen’s stock performance positively, as successful results may boost investor confidence and position the company favorably against competitors in the dermatology and immunology sectors. The study’s findings could also have broader implications for the treatment of atopic dermatitis and vaccine response.

The study is now completed, and further details can be accessed on the ClinicalTrials portal.